Phase 2 N=65 Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Advanced Non-Clear Cell Kidney Cancer
Primary: Best Overall Response Rate — 33 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=142 A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
Renal Cell Carcinoma
Primary: PFS (Progression-Free Survival) — 27.71 Weeks
Phase 2 N=57 Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma
Primary: To Evaluate the Efficacy of Combining Everolimus and Bevacizumab in Patients With Advanced RCC of Non-clear Cell Histology — 78 percent of participants
Phase 2 N=41 Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: 4-month Progression-Free Survival Rate — 65 percentage of participants — p=0.081
Phase 2 N=127 Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
Locally Advanced or Metastatic Renal Cell Carcinoma
Primary: Cohort A: Objective Response Rate (ORR) Assessed by Independent Central Review — 40.5 percentage of participants
Phase 2 N=108 Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
Advanced Non-clear Cell Renal Cell Carcinoma
Primary: Anti-tumor Activity as Measured by Median Progression Free Survival Time — 5.6; 8.3 Months — p=0.157
Phase 2 N=80 Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
Kidney Cancer
Primary: Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease…
Phase 2 N=26 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Kidney Cancer
Primary: Progression Free Survival — 9.6 months
N/A N=1,349 Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan
Renal Cell Carcinoma
Primary: Duration of Sunitinib and Pazopanib Treatment in Participants — 171; 114.5 days
Phase 2 N=96 MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
Clear-cell Metastatic Renal Cell Carcinoma
Primary: Progression-Free Survival (PFS) — 3.8; 3.6; 3.1 months — p==0.388
Phase 2 N=20 Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Primary: Percentage of Participants Who Achieved a Point in Time Objective Response (Either Complete or Partial Response [CR or PR]) Prior to Surgery — 2; 0 Participants
Phase 2 N=168 BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) — 2.63; 4.11; 4.17 Months
Phase 2 N=164 Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Primary: 1-year Progression Free Survival (PFS) Rate for ccRCC Patients — 34.6; 53.8; 33.3; 75 Percentage of participants
Phase 2 N=134 Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Progression-free Survival (PFS) - All Participants — 7.4 months
Phase 2 N=15 BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Phase I: Maximum Tolerated Dose of BNC105P in Combination With Everolimus. — 16 mg/m^2
Phase 2 N=94 Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Primary: Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 17 percentage of participants
Phase 2 N=50 Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: Progression Free Survival (PFS) — 11 months
Phase 2 N=119 High-dose Bevacizumab in Advanced Renal Carcinoma Patients
Renal Cancer · Kidney Cancer
Primary: Progression-free Survival — 6.0; 5.7 months
Phase 2 N=25 SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients
Kidney Cancer Metastatic · Kidney Cancer · Kidney Cancer, Stage IV
Primary: Number of Participants With Treatment-related Adverse Events Grade 3 or Higher as Assessed by CTCAE v4.0 — 9 Participants
Phase 2 N=57 Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
Renal Cell Cancer · Kidney Cancer
Primary: Number of Participants With Response to Treatment — 0; 3; 29; 23 participants
Phase 2 N=105 A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Biomarkers in Blood and Archived Tissue Samples, and Their Correlation With Clinical Activity in Subjects With Advanced Renal Cell Cancer Treated With Tivozanib.
Phase 2 N=69 CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
Clear Cell Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) — 1.91; 3.81 months — p=0.07905
Phase 2 N=39 Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma · Renal Cell Carcinoma With Sarcomatoid Features
Primary: Response Rate by Solid Tumor Response Criteria (RECIST) — 16 Percentage of Participants
Phase 2 N=45 SLM + Axitinib for Clear Cell RCC
Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
Primary: Incidence of Adverse Events (AE) Per CTCAE 4.03 — 3; 5; 7; 20 Participants
Phase 2 N=10 Carfilzomib in Refractory Renal Cell Carcinoma (RCC)
Kidney Cancer
Primary: Progression Free Survival (PFS) of Carfilzomib Therapy in Participants With Refractory Or Intolerant to Prior Therapy — 1.8 Months
Phase 2 N=160 Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
Renal Cell Carcinoma
Primary: Objective Response Rate (ORR) — 50.6 Percentage of participants
Phase 2 N=69 Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
Kidney Cancer
Primary: Progression Free Survival (PFS) — 2.7; 5.2 months
Phase 3 N=821 Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Primary: Overall Survival (OS) at Primary Endpoint — 25.00; 19.55 months — p=0.0018
Phase 2 N=146 A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
Renal Cell Cancer
Primary: Progression-Free Survival (PFS) - Percentage of Participants Estimated to be Progression Free at 12 and 24 Months — 58.2; 28.9 percentage of participants
Phase 2 N=275 Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
Renal Cell Carcinoma
Primary: Objective Response Rate (ORR) — 36.4; 26.7 Percentage of Participants